CO6551713A2 - Derivados de difenil -pirazolopiridinas, su preparación y su aplicación como moduladores del receptor nuclear not - Google Patents
Derivados de difenil -pirazolopiridinas, su preparación y su aplicación como moduladores del receptor nuclear notInfo
- Publication number
- CO6551713A2 CO6551713A2 CO12093017A CO12093017A CO6551713A2 CO 6551713 A2 CO6551713 A2 CO 6551713A2 CO 12093017 A CO12093017 A CO 12093017A CO 12093017 A CO12093017 A CO 12093017A CO 6551713 A2 CO6551713 A2 CO 6551713A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- group
- hydroxyalkyl
- hydrogen
- pirazolopiridinas
- Prior art date
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 101001109698 Homo sapiens Nuclear receptor subfamily 4 group A member 2 Proteins 0.000 abstract 2
- 102100022676 Nuclear receptor subfamily 4 group A member 2 Human genes 0.000 abstract 2
- -1 cyano, hydroxy Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000005188 oxoalkyl group Chemical group 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 101000785650 Homo sapiens Zinc finger protein 268 Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 108010093175 Member 2 Group A Nuclear Receptor Subfamily 4 Proteins 0.000 abstract 1
- 102000002559 Member 2 Group A Nuclear Receptor Subfamily 4 Human genes 0.000 abstract 1
- 101001109694 Rattus norvegicus Nuclear receptor subfamily 4 group A member 2 Proteins 0.000 abstract 1
- 102100026516 Zinc finger protein 268 Human genes 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 229910052736 halogen Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a compuestos de la fórmula (I), en la que R es un átomo de hidrógeno o un halógeno o un grupo alquilo(C1-C6); X representa uno o varios sustituyentes elegidos entre un átomo de hidrógeno o de halógeno, un grupo alquilo(C1-C6), halogenoalquilo(C1-C6), alcoxi(C1-C6), halogenoalcoxi(C1-C6), ciano, hidroxi o hidroxialquilo(C1 -C6); Y representa un átomo de hidrógeno, de halógeno o un grupo alquilo(C1-C6); R1 representa un grupo NR2R3 o OR4; R2 y R3 representan, independientemente entre sí, un átomo de hidrógeno, un grupo alquilo(Cl-C6), hidroxialquilo(C1-C6) u oxoalquilo(C1-C6), o bien R2 y R3 forman con el átomo de nitrógeno que los lleva un heterociclo opcionalmente sustituido con un grupo alquilo(C1- C6), hidroxi u oxo; y R4 representa un grupo alquilo(C1-C6), hidroxialquilo(C1-C6) u oxoalquilo(C1-C6), en forma de base o de sal de adición a un ácido. Dicha fórmula puede ser usada terapéuticamente en el tratamiento o en la prevención de enfermedades que implican a los receptores nucleares Nurr-1, denominados también NR4A2, NOT, TINUR, RNR-1, y HZF3.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0958651A FR2953520B1 (fr) | 2009-12-04 | 2009-12-04 | Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6551713A2 true CO6551713A2 (es) | 2012-10-31 |
Family
ID=42111360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO12093017A CO6551713A2 (es) | 2009-12-04 | 2012-06-04 | Derivados de difenil -pirazolopiridinas, su preparación y su aplicación como moduladores del receptor nuclear not |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8680096B2 (es) |
| EP (1) | EP2507238B1 (es) |
| JP (1) | JP5738310B2 (es) |
| KR (1) | KR101696959B1 (es) |
| CN (1) | CN102762559B (es) |
| AR (1) | AR079250A1 (es) |
| AU (1) | AU2010326429B2 (es) |
| BR (1) | BR112012013511A2 (es) |
| CA (1) | CA2782704C (es) |
| CL (1) | CL2012001461A1 (es) |
| CO (1) | CO6551713A2 (es) |
| EA (1) | EA020652B1 (es) |
| FR (1) | FR2953520B1 (es) |
| HK (1) | HK1169984A1 (es) |
| IL (1) | IL220060A (es) |
| JO (1) | JO3098B1 (es) |
| MA (1) | MA33893B1 (es) |
| MX (1) | MX2012006421A (es) |
| MY (1) | MY157676A (es) |
| NZ (1) | NZ600368A (es) |
| SG (1) | SG181138A1 (es) |
| TW (1) | TWI481606B (es) |
| UY (1) | UY33079A (es) |
| WO (1) | WO2011067544A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2950344B1 (fr) * | 2009-09-18 | 2011-11-25 | Sanofi Aventis | Derives de 5-phenyl-pyrazolopyridine, leur preparation et leur aplication en therapeutique. |
| FR2950345B1 (fr) * | 2009-09-18 | 2011-09-23 | Sanofi Aventis | Derives acetyleniques de 5-phenyl-pyrazolopyridine, leur preparation et leur application en therapeutique |
| BR112019010880A2 (pt) | 2016-11-28 | 2019-10-01 | Praxis Prec Medicines Inc | compostos e seus métodos de uso |
| US20210188839A1 (en) * | 2016-11-28 | 2021-06-24 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11261188B2 (en) | 2016-11-28 | 2022-03-01 | Praxis Precision Medicines, Inc. | Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel |
| WO2018104214A1 (de) * | 2016-12-08 | 2018-06-14 | Bayer Cropscience Aktiengesellschaft | Verfahren zur herstellung von 5-(1-phenyl-1h-pyrazol-4-yl)-nicotinamid-derivaten und ähnlicher verbindungen ohne isolierung oder aufreinigung der phenylhydrazin-zwischenstufe |
| US11492345B2 (en) | 2017-02-13 | 2022-11-08 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2018187480A1 (en) | 2017-04-04 | 2018-10-11 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11278535B2 (en) | 2017-08-15 | 2022-03-22 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| CN112423760A (zh) | 2018-05-30 | 2021-02-26 | 普拉克西斯精密药物股份有限公司 | 离子通道调节剂 |
| US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
| US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| US11767325B2 (en) | 2019-11-26 | 2023-09-26 | Praxis Precision Medicines, Inc. | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators |
| CN111138325B (zh) * | 2019-12-20 | 2021-11-30 | 台州学院 | 一种(Z)-β-磺酰基烯胺类化合物的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001139575A (ja) * | 1999-11-15 | 2001-05-22 | Fujisawa Pharmaceut Co Ltd | 新規ピラゾロピリジン誘導体 |
| FR2906250B1 (fr) * | 2006-09-22 | 2008-10-31 | Sanofi Aventis Sa | Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique |
| PL2121687T3 (pl) * | 2006-12-22 | 2016-03-31 | Astex Therapeutics Ltd | Pochodne amin tricyklicznych jako inhibitory białkowej kinazy tyrozynowej |
| FR2928923B1 (fr) * | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques |
| FR2928921B1 (fr) * | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives polysubstitues de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines, leur preparation et leur application en therapeutique |
| FR2928924B1 (fr) * | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique |
| US8198449B2 (en) * | 2008-09-11 | 2012-06-12 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| FR2950344B1 (fr) * | 2009-09-18 | 2011-11-25 | Sanofi Aventis | Derives de 5-phenyl-pyrazolopyridine, leur preparation et leur aplication en therapeutique. |
-
2009
- 2009-12-04 FR FR0958651A patent/FR2953520B1/fr not_active Expired - Fee Related
-
2010
- 2010-12-02 JO JOP/2010/0430A patent/JO3098B1/ar active
- 2010-12-03 EP EP10801625.4A patent/EP2507238B1/fr not_active Not-in-force
- 2010-12-03 CA CA2782704A patent/CA2782704C/fr not_active Expired - Fee Related
- 2010-12-03 SG SG2012039749A patent/SG181138A1/en unknown
- 2010-12-03 WO PCT/FR2010/052605 patent/WO2011067544A1/fr active Application Filing
- 2010-12-03 US US13/513,497 patent/US8680096B2/en not_active Expired - Fee Related
- 2010-12-03 CN CN201080062600.0A patent/CN102762559B/zh not_active Expired - Fee Related
- 2010-12-03 KR KR1020127017287A patent/KR101696959B1/ko active IP Right Grant
- 2010-12-03 AU AU2010326429A patent/AU2010326429B2/en not_active Ceased
- 2010-12-03 EA EA201290520A patent/EA020652B1/ru not_active IP Right Cessation
- 2010-12-03 NZ NZ600368A patent/NZ600368A/en not_active IP Right Cessation
- 2010-12-03 MX MX2012006421A patent/MX2012006421A/es active IP Right Grant
- 2010-12-03 TW TW099142230A patent/TWI481606B/zh not_active IP Right Cessation
- 2010-12-03 AR ARP100104462A patent/AR079250A1/es unknown
- 2010-12-03 UY UY33079A patent/UY33079A/es not_active Application Discontinuation
- 2010-12-03 JP JP2012541567A patent/JP5738310B2/ja not_active Expired - Fee Related
- 2010-12-03 MY MYPI2012002449A patent/MY157676A/en unknown
- 2010-12-03 BR BR112012013511A patent/BR112012013511A2/pt not_active IP Right Cessation
- 2010-12-03 MA MA35024A patent/MA33893B1/fr unknown
-
2012
- 2012-05-30 IL IL220060A patent/IL220060A/en not_active IP Right Cessation
- 2012-06-04 CL CL2012001461A patent/CL2012001461A1/es unknown
- 2012-06-04 CO CO12093017A patent/CO6551713A2/es active IP Right Grant
- 2012-10-22 HK HK12110468.8A patent/HK1169984A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IL220060A (en) | 2015-05-31 |
| CA2782704A1 (fr) | 2011-06-09 |
| AU2010326429A1 (en) | 2012-06-21 |
| MY157676A (en) | 2016-07-15 |
| AR079250A1 (es) | 2012-01-04 |
| KR20120103672A (ko) | 2012-09-19 |
| NZ600368A (en) | 2013-12-20 |
| EA201290520A1 (ru) | 2013-01-30 |
| UY33079A (es) | 2011-06-01 |
| EA020652B1 (ru) | 2014-12-30 |
| JO3098B1 (ar) | 2017-03-15 |
| HK1169984A1 (en) | 2013-02-15 |
| AU2010326429B2 (en) | 2016-07-14 |
| JP5738310B2 (ja) | 2015-06-24 |
| US20120245164A1 (en) | 2012-09-27 |
| CA2782704C (fr) | 2018-01-02 |
| EP2507238A1 (fr) | 2012-10-10 |
| CL2012001461A1 (es) | 2012-10-12 |
| KR101696959B1 (ko) | 2017-01-16 |
| CN102762559A (zh) | 2012-10-31 |
| US8680096B2 (en) | 2014-03-25 |
| SG181138A1 (en) | 2012-07-30 |
| MA33893B1 (fr) | 2013-01-02 |
| CN102762559B (zh) | 2014-11-05 |
| EP2507238B1 (fr) | 2013-07-31 |
| FR2953520A1 (fr) | 2011-06-10 |
| FR2953520B1 (fr) | 2011-11-25 |
| TWI481606B (zh) | 2015-04-21 |
| MX2012006421A (es) | 2012-10-09 |
| JP2013512884A (ja) | 2013-04-18 |
| BR112012013511A2 (pt) | 2016-06-07 |
| WO2011067544A1 (fr) | 2011-06-09 |
| TW201129564A (en) | 2011-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6551713A2 (es) | Derivados de difenil -pirazolopiridinas, su preparación y su aplicación como moduladores del receptor nuclear not | |
| ES2600636T3 (es) | Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2 | |
| CR10784A (es) | Nuevos derivados de aminopirimidina como inhibidores de plki | |
| AR076754A1 (es) | Dihidropirimidinas y proceso de obtencion de las mismas | |
| PE20130376A1 (es) | [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer | |
| PE20141358A1 (es) | Polimorfos de inhibidores de cinasas | |
| BRPI0818193B8 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| NZ629025A (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists | |
| AR081649A1 (es) | Compuestos heteroarilo nitrogenados | |
| AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| AR049346A1 (es) | 3-amino-1-arilpropil-indoles como inhibidores de reabsorcion de monoaminas | |
| AR088226A1 (es) | Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas | |
| ECSP11011365A (es) | Sales de adición de aminas que contienen grupos hidroxilo y/o carboxílicos con derivados de ácido aminonicotínico como inhibidores de dhodh | |
| ES2530943T3 (es) | Derivados de la cromenona con actividad antitumoral | |
| BRPI0814065B8 (pt) | derivados de alcoóis de 1-fenil-2-piridinil alquila como inibidores da fosfodiesterase | |
| SG195319A1 (en) | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors | |
| AR076008A1 (es) | Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos. | |
| AR077534A1 (es) | Derivados de isoxazol, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con el receptor gaba aalfa5 | |
| ECSP099216A (es) | Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| ECSP10010380A (es) | Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| ES2439793T3 (es) | Compuestos de pirimidina, su uso como inhibidores de la mTOR quinasa y de la PI3 quinasa, y su síntesis | |
| AR072880A1 (es) | Derivados nitrogenados de la pancratistatina | |
| PH12015500003A1 (en) | Indolecarboxamide derivative | |
| AR082054A1 (es) | Derivados aril- y heteroarilamida como inhibidor de enzima pde10a | |
| AR063018A1 (es) | Moduladores de los receptores de la progesterona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |